|Home | About | Journals | Submit | Contact Us | Français|
Beneficial effects of n‐3 fatty acids (FA) on bone mineral density (BMD) have been reported in mice, rats and human beings, but the precise mechanisms involved have not been described. This study used the Fat‐1 mouse, a transgenic model that synthesizes n‐3 FA from n‐6 FA to directly determine if outcome of bone health were correlated with n‐3 FA. Ovariectomized (Ovx) and sham operated wild‐type (WT) and Fat‐1 mice were fed an AIN‐93M diet containing 10% corn oil for 24 weeks. BMD was analysed by dual energy x‐ray absorptiometry. Fat‐1 Ovx mice exhibited significantly lower level of osteotropic factors like receptor activator of NF‐κB ligand and tartrate‐resistant acid phosphatase (TRAP)5b in serum and higher BMD in distal femoral metaphysis, proximal tibial metaphysis, femoral diaphysis and lumbar vertebra as compared to WT Ovx mice. LPS‐stimulated bone marrow (BM) cells from Fat‐1 Ovx mice produced significantly lower level of pro‐inflammatory cytokines like tumour necrosis factor‐α, interleukin (IL)‐1‐β, IL‐6 and higher level of anti‐inflammatory cytokines like IL‐10, IFN‐γ and higher level of nitric oxide as compared to BM cells from WT Ovx mice. LPS‐stimulated COX‐II activity as well as NF‐κB activation in BM cells from Fat‐1 Ovx mice was significantly less as compared to BM cells from WT Ovx mice. Furthermore, Fat‐1 BM cells generated significantly less number of TRAP osteoclast‐like cells as compared to WT BM cells. In conclusion, we offer further insight into the mechanisms involved in preventing the BMD loss in Ovx mice by n‐3 FA using a Fat‐1 transgenic mouse model.
Post‐menopausal osteoporosis due to oestrogen deficiency is a major health problem, primarily because of the severe morbidity and mortality associated with osteoporotic fractures. Oestrogen and/or hormone replacement therapies (ERT and/or HRT) are able to prevent osteoporotic bone loss, however, accompanied by adverse side‐effects, such as uterine, ovarian and breast cancer and increased risk of cardiovascular diseases [1, 2]. Therefore, diet therapies that minimize bone loss would be an ideal alternative.
Recently, there has been increasing evidence that deficiency of certain fatty acids (FA) in the diet may contribute to bone loss [3, 4, 5]. A body of scientific evidence based on results in cell cultures [6, 7], animals [6, 7, 8, 9, 10, 11] and human beings  indicates that long‐chain n‐3 polyunsaturated FA may protect skeletal health and potentially improve conditions associated with osteoporosis. In animal models, it has been shown that n‐3 FA deficiency caused severe osteoporosis . When deficient animals were replenished with n‐3 FA, the ratio of n‐3 to n‐6 FA in bone compartments was restored and the process of bone degradation was reversed . Different dietary ratios of n‐6 to n‐3 FA were tested in piglets and shown that higher n‐3 FA levels in blood were associated with lower bone resorption . In a clinical trial of 65 elderly women whose diet was low in calcium, supplementation with a lower ratio of n‐6 and n‐3 FA plus calcium resulted in decreased bone degradation and increased BMD . In another randomized trial in 40 patients with osteoporosis, individuals taking a supplement rich in n‐3 FA showed better calcium absorption and increased markers of bone formation as compared to placebo group .
We speculate that by modulating the dietary ratio of n‐6/n‐3 FA, bone growth can be optimized.
Mammalian cells can neither synthesize n‐3 FA nor convert n‐6 to n‐3 FA as they lack the converting enzyme, n‐3 desaturase. The consumption of fish rich in n‐3 FA is recommended for its health benefits to protect against heart disease, diabetes and potentially cancer . High‐fat diets are pervasive in Western cultures. American people consume very minimal n‐3 FA in relation to the amount of n‐6 FA. n‐3 FA stimulate production of anti‐inflammatory eicosanoids that attenuate the production of cytokines and associated bone resorption, whereas its cousin in n‐6 FA stimulate production of pro‐inflammatory eicosanoids that stimulate bone resorption by releasing cytokines to activate NF‐κB [12, 16].
In 2004, Kang et al. generated transgenic Fat‐1 mouse (Fat‐1) on C57BL6 background carrying the fat‐1 gene from Caenorhabditis elegans, which encodes for an n‐3 desaturase enzyme that can synthesize n‐3 FA from n‐6 FA . Different tissues of Fat‐1 mice show increase in n‐3 FA and decrease in n‐6 FA leading to a significant decrease in n‐6/n‐3 FA ratio. Thus, Fat‐1 transgenic mice have an n‐6/n‐3 FA ratio of ~1: 1 compared to wild‐type (WT) mice with ratio of 20–30: 1. Preliminary studies with Fat‐1 mouse have already yielded interesting results. We and others have shown that Fat‐1 mice attenuate inflammatory response following bacterial lipopolysaccharide (LPS) challenge [18, 19]. To examine the effect of FA, dietary lipid feeding studies using an intact animal model system are useful; however, these are confounded by the need to formulate isocaloric diets with respect to fat content. In addition, to formulate diets with different n‐6 to n‐3 ratios requires the blending of several oil sources; thus, the fat composition between control and experimental diets is difficult to control. The Fat‐1 mouse model is not subject to these potential confounders, given that Fat‐1 mice can endogenously synthesize n‐3 FA; thus, only one diet needs to be provided to both WT and Fat‐1 mice. Thus, the Fat‐1 mouse represents a significant advance in the development of a more sophisticated research model to investigate the effect of n‐3 FA and n‐6/n‐3 FA ratio on physiological parameters, inflammation and molecular mechanisms without providing exogenous n‐3 FA in form of fish oil. Although the research on n‐3 FA and bone health is promising, researchers have yet to establish a clear mechanism of action. In this study, we used this Fat‐1 transgenic ovariectomized (Ovx) mouse model to establish n‐3 FA as a preventive drug to post‐menopausal osteoporosis, and to dissect the molecular mechanisms underlying this effect.
Male transgenic Fat‐1 C57BL6 mice were obtained from Dr. Jing Kang at the Harvard Medical School. They were mated with WT C57BL6 female mice to obtain female fat‐1 positive C57BL6 mice (Fat‐1) and fat‐1 negative C57BL6 mice (WT) identified by genotyping using REDExtract‐N‐Amp Tissue PCR Kit from Sigma (St Louis, MO, USA) and analyzing the FA composition of tails by using gas chromatography as described previously . Weight‐matched mice were housed in a laboratory animal care facility in cages (three to four mice/cage) and fed semi‐purified AIN‐93M diets containing 10% corn oil (CO) (MP Biomedicals, Irvine, CA). CO is high in linoleic acid (18: 2n‐6) and Fat‐1 mice convert n‐6 FA to n‐3 FA. The composition of the semi‐purified diet per kilogram of diet was: 140 g of casein, 424.3 g of corn starch, 145 g of dextronized corn starch, 90 g of sucrose, 50 g of fibre, 35 g of AIN‐93 mineral mix, 10 g of AIN‐93 vitamin mix, 1.8 g of L‐cystine and 2.5 g of choline bitartrate. Diets were prepared weekly and stored in aliquots at −20°C. Fresh diet was provided daily, and leftover food was removed to prevent rancidity. At 2 months age, 40 weight‐matched WT mice and Fat‐1 mice were sham operated (10 mice per group) or Ovx (10 mice per group). Forty mice with four groups of 10 were maintained on 10% CO diet for 24 weeks until killing. The National Institutes of Health guidelines provided in ‘The Guide for the Care and Use of Laboratory Animals’ were strictly followed, and all studies were approved by the Institutional Laboratory Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio.
Four weeks before termination of the study, blood was collected retro‐orbitally and serum was separated. Serum receptor activator of NF‐κB ligand (RANKL) and tartrate resistant acid phosphatase (TRAP) were measured using mouse free soluble (s)RANKL and mouse TRAP5b ELISA assay kits from Immunodiagnostic System (IDS) Inc. (Fountain Hills, AZ, USA) according to the manufacturer’s instructions .
BMD was measured by dual energy x‐ray absorptiometry (DEXA) at baseline (8 weeks) and after 24 weeks on 10% CO diet using a Lunar PIXImus mouse bone densitometer (General Electric, Madison, WI, USA) and data analysis was carried out manually with PIXImus software as described previously [21, 22].
Whole bone marrow (BM) cells were aseptically isolated as described elsewhere . Cells were counted and viability was determined by trypan blue exclusion method. Cells (10 × 106/well) were plated in 12‐well plates and bacterial LPS was added at the concentration of 5.0 μg/ml for 24 hrs at 37°C in a humidified atmosphere of air/CO2 95: 5 (mol%). After 24 hrs, cells and culture medium were collected together and centrifuged at 2000 rpm for 5 min. The pellets were stored at –80°C for transcription factor assays and supernatants were analysed for tumour necrosis factor (TNF)‐α,, interleukin (IL)‐1β, IL‐6, IL‐10, interferon (IFN)‐γ and nitric oxide.
Whole BM cells (~1 × 106 cells) were used for the extraction of total lipids by the method of Folch et al. using chloroform: methanol (2: 1) as described previously [24, 25]. FA methyl esters were separated and quantified by gas–liquid chromatography using a Hewlett‐Packard 5890A series II gas chromatograph (Hewlett‐Packard, Palo Alto, CA, USA), equipped with a DB225MS capillary column (J&W Scientific, Folsom, CA, USA). FA methyl esters were identified by comparison of retention times with FA methyl ester standard (FIM‐FAME‐7) from Matreya, Inc. (Pleasant Gap, PA, USA). Quantification was performed by an integrator (Hewlett‐Packard 3396 series II) attached to a gas liquid chromatograhy (GLC) machine, and results were expressed as area percentages.
TNF‐α, IL‐1β, IL‐6, IL‐10 and IFN‐γ were measured by ELISA using BD OptEIA™ ELISA kits from BD Biosciences Pharmingen (San Diego, CA, USA) according to the manufacturer’s instruction.
Nitric oxide was measured in LPS‐treated BM culture supernatant using quantichrome nitric oxide assay kit (DINO‐250) from Bioassay Systems (Hayward, CA, USA).
After 24 hrs of BM culture in the presence of LPS, cells were collected. Cytosolic and nuclear proteins were prepared as described previously . Protein concentrations of the nuclear extracts, and cytosolic extracts were determined using a bicinchoninic acid (BCA) protein assay kit.
One hundred micrograms of cytosolic protein of 24‐hr LPS‐treated BM cells from WT and Fat‐1 mice were analysed for COX‐II activity using CAYMAN COX Activity Assay Kit (Cayman, Ann Arbor, MI, USA) according to the manufacturer’s instruction.
Thirty micrograms of cytosolic extracts were subjected to SDS‐PAGE. Proteins were transferred to immunoblot polyvinylidene difluoride membranes (BioRad, Hercules, CA, USA) and subjected to Western blot analysis. Rabbit polyclonal antibody against IκB‐α and mouse monoclonal antibody against phosphorylated IκB‐α were obtained from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
LPS‐treated BM cells pellets obtained after collecting supernatants were analysed for LPS‐stimulated activation of NF‐κB using NF‐κB transcription factor assay kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer’s instructions. NF‐κB‐DNA binding was analysed for NF‐κB p65 and NF‐κB p50 subunits. Briefly, a total of 10 μg of nuclear extracts were incubated with mild agitation for 1 hr at room temperature with binding buffer in microwells coated with probes containing the NF‐κB consensus binding sequence. The microwells were then washed three times. Anti‐NF‐κB antibody was added to each well and incubated for 1 hr at room temperature. The microwells were then washed three times before being incubated with HRP‐conjugated antibody for 1 hr at room temperature. The microwells were then washed four times and then exposed to tetramethylbenzidine for 10 min. at room temperature before the stop solution was added. The optical density was read at 450 nm using a microplate reader (Dynex Technologies, Worthing, UK).
BM cells from the tibias and femurs of WT and Fat‐1 mice were collected and cultured as described previously by Rahman et al.. Briefly, cells were suspended in α‐MEM containing 15% foetal calf serum and cultured in 48‐well plates (1 × 106 cells/ml). Osteoclast differentiation was induced in the presence of macrophage colony‐stimulating factor (M‐CSF) (20 ng/ml) and sRANKL (30 ng/ml) for 4 days. At the end of the culture, the cells were fixed and then stained with a commercial kit for TRAP (no. 387A; Sigma), a marker enzyme for osteoclast. TRAP+ cells with more than three nuclei were counted as osteoclast (multinucleated cells).
Data are expressed as means ± S.E.M. To test the significance either Student’s t‐test or Newman‐Keuls’ one‐way ANOVA was used. The significance of differences in BMD from baseline to end of study between WT and transgenic groups were analysed by unpaired t‐test. The GraphPad Prism 4.0 was employed for the statistical analyses. Differences were considered significant when P < 0.05.
The fat‐1 gene of C. elegans encodes an n‐3 fatty‐acid desaturase enzyme that converts n‐6 to n‐3 FA and which is absent in most animals, including mammals . Both WT and Fat‐1‐transgenic littermates born to the same mother and were maintained on an identical diet that was high in n‐6 but deficient in n‐3 FA. However, the fatty‐acid profiles of the two groups turned out to be quite different in BM cells (Table 1). During this dietary regime, Fat‐1 mice had significantly higher amounts of n‐3 FA, such as eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA), in BM cells compared with WT mice (Table 1). The ratio of the long‐chain n‐6 FA (18: 2n‐6 + 20: 4n‐6 +22: 4n‐6 + 22: 5n‐6) to the long‐chain n‐3 FA (18: 3n‐3 + 20: 5n‐3 + 22: 5n‐3 + 22: 6n‐3) was 5.9 in Fat‐1 mice and 20.6 in WT mice and an arachidonic acid (AA)/(EPA+DPA+DHA) ratio of 0.92 versus 4.84. This means transgene is functionally active in vivo and transmittable.
We measured the sRANKL and TRAP5b levels in serum collected retro‐orbitally 4 weeks before termination of the study to determine the bone resorbing status in sham and Ovx mice. RANKL is one of the most pivotal osteoclastogenic factors [27, 28] and serum TRAP5b level indicates the current status of osteoclasts function, i.e. TRAP activity. Interestingly, we found both serum RANKL and TRAP5b levels were significantly less in Fat‐1 Ovx mice than in WT Ovx mice (Fig. 1A and B). The results indicate that the key bone resorbing osteoclastogenic factors are reduced due to the presence of endogenous n‐3 FA, which supports the earlier findings that n‐3 FA down‐regulate osteoclastogenic factors [10, 29].
We have examined the baseline BMD of different bone regions prior to sham and Ovx surgery using DEXA. There were no differences in baseline BMD values among the groups (data not shown). To examine the effect of endogenous n‐3 FA on Ovx‐induced bone loss, we measured the BMD of femur, tibia and lumber regions 24 weeks after sham and Ovx surgery using DEXA. The results are shown in Table 2. The BMD in the distal end of the femur, the proximal end of the tibia and the lumbar regions of the spine of WT Ovx mice were significantly lower than that in WT sham mice. The BMD of different regions of Fat‐1 Ovx mice was also lower than in Fat‐1 sham mice. However, the reduction in BMD was not significant. Comparing between WT Ovx mice (without endogenous n‐3 FA production) and Fat‐1 Ovx mice (with endogenous n‐3 FA production), the BMD loss was significantly higher in femoral, tibial and third lumber regions of the WT mice group. Thus, lower ratio of n‐6/n‐3 FA due to endogenous production of n‐3 FA maintains higher BMD in Fat‐1 Ovx mice compared to WT Ovx mice. These findings indicate that Fat‐1 mice, rich in n‐3 FA, are at least better protected in oestrogen deficient BMD loss. To confirm the oestrogen status of the Ovx or sham mice, the uterine wet weight was measured at the time of killing. Ovariectomy performed in 8‐week‐old mice significantly decreased the uterus weight of both WT and Fat‐1 mice (data not shown). The fat‐1 transgene had no effect on the uterus weight of sham or Ovx mice.
We next examined whether the Ovx‐induced BMD loss protection observed in Fat‐1 mice had an impact on bone resorbing inflammation‐related cytokines expression. Pro‐inflammatory cytokines like IL‐1β, IL‐6 and TNF‐α are key regulators of osteoclastogenic activity and have been shown to increase bone resorption [30, 31, 32]. Interestingly, we found significant increase in IL‐1β and TNF‐α production by BM cells of WT Ovx mice than that of WT sham mice, whereas no increase of these cytokines was observed in Fat‐1 Ovx mice when compared to Fat‐1 sham mice (Fig. 2). However, there was no significant difference in IL‐6 production between the sham and Ovx mice in both WT and Fat‐1 groups. Significantly higher level of IL‐1β, TNF‐α and IL‐6 was observed in WT Ovx mice when compared to Fat‐1 Ovx mice. Surprisingly, we found significantly lower level of TNF‐α in Fat‐1 Ovx group than in Fat‐1 sham group. We then examined if reduced n‐6/n‐3 FA ratio due to endogenous conversion of n‐6 to n‐3 FA can stimulate the production of anti‐inflammatory cytokines like IL‐10 and IFN‐γ. IL‐10 is reported to inhibit bone resorption in inflammatory disorders [33, 34] and IFN‐γ is a strong suppressor of osteoclastogenesis . Interestingly, we observed significantly higher level of both IL‐10 and IFN‐γ production by BM cells of Fat‐1 Ovx mice when compared to WT Ovx mice (Fig. 2). The results indicate that the reduction of n‐6/n‐3 FA ratio may prevent Ovx‐induced BMD loss indirectly by inhibiting the production of osteoclastogenic pro‐inflammatory cytokines and by enhancing the production of anti‐osteoclastogenic anti‐inflammatory cytokines.
Nitric oxide has been reported to be a potent anti‐osteoclastogenic and anti‐osteoporotic in severe inflammatory and oestrogen deficient animals. Therefore, we next determined if there is any effect of endogenous n‐3 FA on LPS‐stimulated nitric oxide production by BM cells. Interestingly, we observed higher levels of nitric oxide production in BM cells from Fat‐1 mice both sham and Ovx than from WT mice (Fig. 3). That might be another anti‐osteoclastogenic mechanism exerted by endogenous n‐3 FA to protect Ovx‐induced BMD loss.
Over expression of COX‐II stimulates osteoclastogenesis and bone resorption  and n‐3 FA are reported to down‐regulate COX‐II expression. Therefore, we examined whether lower ratio of n‐6/n‐3 FA due to endogenous production of n‐3 FA also have the COX‐II reducing ability which might be one of the mechanisms by which it is attenuating osteoclastogenesis and bone resorption. Interestingly, we found significant reduction of COX‐II activity in LPS‐treated BM cells from Fat‐1 mice as compared to WT mice (Fig. 4).
We further examined whether endogenous n‐3 FA had any impact on the activation of NF‐κB signalling. NF‐κB is one of the most vital transcription factor associated with inflammatory bone destruction . NF‐κB activation is regulated by three major steps, phosphorylation of I‐κBα, I‐κBα degradation and nuclear translocation of p50/p65 subunits. LPS‐stimulated I‐κBα phosphorylation and I‐κBα degradation in BM cells were analysed by western blot. Both I‐κBα phosphorylation and I‐κBα degradation were significantly lower in Fat‐1 Ovx group when compared to WT Ovx group (Fig. 5A). Phosphorylation of I‐κBα was significantly higher in WT Ovx as compared to WT sham (Fig. 5A). However, there was no significant difference in I‐κBα phosphorylation and I‐κBα degradation between Fat‐1 Ovx and sham groups (Fig. 5A). LPS‐stimulated activation of p65 and p50 NF‐κB subunits were also analysed using transcription factor assay kit. Interestingly, LPS‐stimulated activation of both p65 and p50 NF‐κB were significantly lower in Fat‐1 Ovx group than in WT Ovx group (Fig. 5B). Surprisingly, significantly lower level of activated p65 NF‐κB was observed in Fat‐1 Ovx group as compared to Fat‐1 sham group (Fig. 5B).
Mouse BM cells can differentiate into TRAP+ osteoclasts‐like cells in the presence of RANKL and M‐CSF . We examined if endogenous n‐3 FA have any effect on RANKL‐stimulated osteoclast formation. Interestingly, significant reduction of osteoclasts formation was observed in BM cultures from Fat‐1 mice as compared to WT mice (Fig. 6A and 6B).
The present study was designed to examine the effect of an endogenously decreased n‐6/n‐3 FA status due to endogenous conversion of n‐6 to n‐3 FA on Ovx‐induced BMD loss in Fat‐1 mice versus WT control littermates. This study demonstrated that higher n‐3 FA and lower n‐6/n‐3 FA level in BM phospholipids in Fat‐1 mice could maintain higher BMD in oestrogen deficient condition when compared to that of WT mice. The decreased BMD loss in femur, tibia and lumbar regions of Fat‐1 mice was accompanied by a lower incidence of osteoclastogenesis. These changes were, on a molecular level, accompanied by a lower activation NF‐κB together with lower activity of COX‐II, reduced production of pro‐inflammatory cytokines TNF‐α, IL‐6 and IL1‐β, increased production of anti‐inflammatory cytokines IL‐10, IFN‐γ and increased production of nitric oxide in BM cells of Fat‐1 mice. We previously showed that dietary n‐3 FA fed mice exhibit less Ovx‐induced BMD loss accompanied by decreased osteoclastogenesis . The molecular mechanisms underlying this protective effect are not clear yet. As Fat‐1 transgenic mouse model eliminates confounding factors between control and experimental diets, we have chosen the Fat‐1 transgenic mice to elucidate the molecular mechanisms underlying the protective effect of increased n3 and decreased n‐6/n‐3 FA tissue status.
The relative ratio between n‐6 and n‐3 FA is an important determinant in the overall health benefits of consuming n‐3 FA [38, 39]. The n‐6 to n‐3 ratio consumed in the present Western diet is between 10: 1 and 20: 1; however, our ancestors had a diet closer to 1: 1 . A lower n‐6 to n‐3 FA ratio may be optimal for one’s health. Efforts have been made to incorporate n‐3 FA into the food supply because of their health benefits and concern over the high n‐6: n‐3 FA in Western diets . We observed a marked reduction in the n‐6 to n‐3 ratio in Fat‐1 mice as compared to WT mice. The n–6 FA, especially AA, is a precursor of prostaglandins (PGs), leukotrienes and related compounds that influence the synthesis of eicosanoids which may enhance inflammation and bone loss [10, 18]. There was a trend towards higher levels of EPA, DPA and DHA and reduced levels of AA in Fat‐1 mice, suggesting that elongation and desaturation were inhibited by the presence of n‐3 FA. Consuming increased amounts of n–3 FA results in a partial replacement of the AA in cell membranes by EPA and DHA [18, 26]. This leads to decreased production of AA‐derived pro‐inflammatory mediators, i.e. PGE2. Dr. Kang group has already established that transgenic overexpression of fat‐1 gene lowers PGE2 expression in both cells and tissues by reducing the availability of AA [41, 42, 43]. COX‐II is the key enzyme responsible for the conversion of AA to PGE2 and selective inhibition of COX‐II can attenuate osteoclastogenesis as well as bone loss in inflammatory bone diseases [44, 45, 46, 47]. It has been further reported that n‐3 FA can down‐regulate COX‐II activity and also lower the production of PGE2 in local tissues [41, 48]. We have also found significantly reduced COX‐II activity in Fat‐1 mice. Thus, modification of membrane FA composition is one of the mechanisms by which n‐3 FA may protect osteoporotic BMD loss possibly by reducing the pro‐inflammatory mediators.
We and others earlier have described the inhibition of pro‐inflammatory cytokines production by n‐3 FA in cells and tissues [10, 48, 49, 50]. Our present data also show significant reduction of inflammatory cytokines production in LPS‐treated BM cells from Fat‐1 mice. This correlates well with previous findings of inflammatory cytokine suppression by n‐3 FA [18, 41, 51, 52]. Our present data also show a significant increase in the LPS‐stimulated production of IL‐10 and IFN‐γ in BM cells. IL‐10 has a critical role in the in vivo regulation of pro‐inflammatory cytokine levels and has been reported to suppress osteoclastogenesis . Further, IFN‐γ is also known to suppress osteoclastogenesis . In addition, nitric oxide is postulated to play an important role in bone metabolism, and it is also known that both EPA and DHA enhance nitric oxide formation [3, 54, 55]. We have also detected higher level of nitric oxide production in Fat‐1 mice. It was reported that osteoclast formation and bone resorption were inhibited by elevated levels of nitric oxide in vivo and in vitro[56, 57, 58, 59, 60]. Moreover, high nitric oxide levels and nitric oxide generating compounds inhibit osteoclast formation and bone resorption and prevent bone loss in severe inflammation or oestrogen‐deficient animals [57, 61, 62, 63, 64]. Further, iNOS deficiency or pharmacological inhibition of nitric oxide can accelerate osteoclast formation and bone resorption in vivo and in vitro, decrease normal bone mass, exacerbate bone destruction in arthritis or osteoporosis models, interfere with normal fracture healing and also iNOS knockout mice are known to exhibit more alveolar bone loss [65, 66, 67]. Thus, this might be another mechanism of the anti‐osteoporotic action of n‐3 FA.
It is now clearly emerging that n–3 FA might exert their effects on inflammatory gene expression through direct actions on the intracellular signalling pathways. Previous studies have shown that n–3 FA can down‐regulate the activity of NF‐κB. It has been reported that EPA prevents TNF‐α‐induced activation of NF‐κB in cultured pancreatic cells . In another study, EPA was reported to decrease endotoxin‐induced activation of NF‐κB and mitogen activated protein kinases (MAPK) in human monocytes [69, 70, 71]. Previously, we have also reported that EPA and DHA alone or in combination inhibits RANKL‐induced NF‐κB activation in BM cells . Others have also showed that fish oil can inhibit LPS‐induced NF‐κB activation in a macrophage cell line . These observations suggest direct effects of n–3 FA on inflammatory gene expression through the inhibition of NF‐κB activation. In this study, we also observed reduced NF‐κB activation in BM cells of Fat‐1 mice compared to that of WT mice. The role of NF‐κB in the pathogenesis of osteoporosis is well documented. Mice null for NF‐κB developed osteopetrosis and contain very few osteoclasts compared with normal controls . This indicates the essential role of the NF‐κB signalling pathway in osteoclast generation and activation [74, 75]. Activation of p38 MAPK and cJun N terminal kinase (JNK) is required for osteoclastogenesis . The p38 MAPK pathway is also known to be involved in the regulation of bone resorption induced by oestrogen deficiency and selective inhibitors of this pathway have potential for prevention of bone loss in post‐menopausal osteoporosis . In a very recent study, we have found decreased activation of p38 MAPK and JNK in n‐3 FA‐treated BM cells (data not shown). Therefore, the observed protection of BMD loss due to oestrogen deficiency by increased n‐3 FA and reduced n‐6/n‐3 FA tissue status is probably due to the reduced activation of NF‐κB, and MAPK signalling pathways.
We previously reported that n‐3 FA inhibited TRAP activity and osteoclast formation in primary BM cells . In our present study, we found that higher endogenous n‐3 FA and lower endogenous n‐6/n‐3 FA status in BM cells commensurate with lower RANKL‐stimulated BM osteoclastogenesis. Stimulation of osteoclast differentiation is one of the mechanisms by which oestrogen deficiency causes bone loss [27, 28, 32, 77]. Thus, reduction of osteoclastogenesis might be one of the mechanisms by which n‐3 FA exert its protection against osteoporotic BMD loss.
Our studies on Fat‐1 transgenic mice provide compelling evidence for the effectiveness of n‐3 FA to be a novel dietary FA to prevent post‐menopausal osteoporosis. Endogenous conversion of n‐6 FA to n‐3 FA and maintaining lower ratio of n‐6/n‐3 FA not only prevents BMD loss in Ovx mice but also inhibits the inflammatory response that underlies the disease. As human beings cannot synthesize n‐3 FA, they can however lower the n‐6/n‐3 FA ratio by consuming more n‐3 FA, either as supplement or via foods enriched with n‐3 FA, to prevent osteoporotic BMD loss. However, extensive pharmacological evaluation of this approach is required to fully determine the effect of long‐term use of n‐3 FA to prevent osteoporosis and related inflammatory bone loss. Very recently, fish oil rich in n‐3 FA has been approved by the Food and Drug Administration (FDA) to use as a prescription drug to treat high triglyceride level as well as for cardiovascular diseases . Because n‐3 FA has many other beneficial effects, such as cardioprotective effect , anti‐carcinogenic effect , triglyceride lowering effect [78, 80], as well as protective effect against inflammatory diseases [19, 81], supplementation with n‐3 FA to prevent osteoporotic bone loss is a new strategy worth pursuing soon.
We thank Kazi Nishu for her technical help. This study was supported by RO1 AG023648.